<DOC>
	<DOCNO>NCT00003428</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use arzoxifene hydrochloride may fight breast cancer block use estrogen tumor cell . PURPOSE : This randomized phase II trial compare two different dos arzoxifene hydrochloride see well work treat woman advance metastatic breast cancer .</brief_summary>
	<brief_title>Hormone Therapy Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare response rate clinical benefit rate patient locally advance metastatic breast cancer treat 1 2 different dos arzoxifene hydrochloride . II . Compare response rate clinical benefit rate patient tamoxifen-sensitive versus tamoxifen-refractory disease . III . Compare degree toxicity 2 dos arzoxifene hydrochloride patient . IV . Compare quality life survival patient receive high versus low dose arzoxifene hydrochloride . V. Determine time progressive disease , time treatment failure , response duration treatment patient . VII . Measure change serum estradiol , follicle stimulate hormone , luteinizing hormone , sex hormone bind globulin patient treatment . OUTLINE : This randomize , double blind study . Patients stratify accord number metastatic site ( less 3 v 3 ) , tamoxifen sensitivity ( sensitive v refractory ) , degree estrogen receptor positivity ( high v low vs unknown ) . Patients randomize receive 1 2 dos arzoxifene hydrochloride . Patients receive arzoxifene hydrochloride orally daily 12 week . Treatment continue absence toxicity disease progression . Quality life assess , , completion study . Patients follow every 4 week 12 week , 30 day last treatment , every 2-3 month last treatment . PROJECTED ACCRUAL : This study accrue 104-114 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally advanced metastatic breast cancer meet one follow criterion : No prior systemic therapy OR Relapsed 12 month stop adjuvant tamoxifen ( tamoxifen sensitive ) OR Relapsed receive adjuvant tamoxifen 12 month ( tamoxifenrefractory ) OR Disease progression receive tamoxifen firstline treatment metastatic breast cancer ( tamoxifenrefractory ) Evaluable bidimensionally measurable disease No rapid disease progression require chemotherapy Brain metastases allow stable least 6 month surgery radiotherapy , increase corticosteroid Hormone receptor status : Estrogen receptor positive AND/OR Progesterone receptor positive OR Unknown status allow 50 year old PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : At least 24 week Hematopoietic : Granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL , transfusion independent Hepatic : Bilirubin great 1.5 time normal PT/PTT great 1.25 time upper limit normal ( ULN ) ALT/AST great 2.5 time ULN Renal : Creatinine le 1.5 time ULN Calcium great 11 mg/dL No hypercalcemia Other : Not pregnant nursing Fertile patient must use approve nonhormonal contraceptive 3 month study No known predisposition thromboembolic disorder At least 5 year since primary malignancy except : Adequately treat nonmelanomatous skin cancer Carcinoma situ cervix No serious concurrent systemic disorder incompatible study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Concurrent hematopoietic growth factor allow Chemotherapy : No prior chemotherapy metastatic breast cancer No concurrent chemotherapy Endocrine therapy : No prior hormonal therapy metastatic breast cancer ( except tamoxifen ) No concurrent supplemental estrogen progesterone At least 3 week since prior estrogen replacement therapy No concurrent hormone therapy Radiotherapy : At least 2 week since prior radiotherapy Surgery : Not specify Other : At least 4 week since prior use investigational agent Concurrent bisphosphonate therapy allow No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>